ストックスクリーナーアプリを入手
25.41
0.66%
-0.31
前日終値:
$25.72
開ける：
$25.94
24時間の取引高:
237.41K
Relative Volume:
0.20
時価総額：
$3.12B
収益：
$460.48M
当期純損益:
$142.80M
株価収益率:
21.53
EPS:
1.18
ネットキャッシュフロー:
$221.79M
1週間 パフォーマンス:
+13.05%
1か月 パフォーマンス:
+24.15%
6か月 パフォーマンス:
+28.07%
1年 パフォーマンス:
+62.22%
1日の値動き範囲:
$25.41
$25.96
1週間の範囲:
$22.21
$26.16
52週間の値動き範囲:
$14.47
$26.16
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
名前
Catalyst Pharmaceuticals Inc
セクター
電話
(305) 529-2522
住所
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
25.41 | 3.12B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.93 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.88 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
588.01 | 35.74B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
272.55 | 35.58B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.09 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-03-14 | 開始されました | Citigroup | Buy |
| 2024-03-07 | 開始されました | BofA Securities | Buy |
| 2023-12-21 | 開始されました | Oppenheimer | Outperform |
| 2022-08-24 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 再開されました | Piper Jaffray | Overweight |
| 2016-10-05 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2013-10-21 | 繰り返されました | Aegis Capital | Buy |
| 2013-09-24 | 開始されました | Maxim Group | Buy |
| 2013-09-06 | 繰り返されました | Aegis Capital | Buy |
| 2013-04-18 | 開始されました | Aegis Capital | Buy |
| 2012-08-27 | アップグレード | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | アップグレード | Merriman | Sell → Neutral |
| 2009-05-29 | ダウングレード | Hapoalim | Neutral → Underperform |
| 2009-05-29 | ダウングレード | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 開始されました | Merriman Curhan Ford | Buy |
| 2007-11-28 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 開始されました | Stifel Nicolaus | Buy |
| 2007-01-05 | 開始されました | First Albany | Buy |
すべてを表示
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - Simply Wall St
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Gary Ingenito Sells 44,904 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - Defense World
Where are the Opportunities in (CPRX) - Stock Traders Daily
Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Executive VP & Chief Commercial Officer Jeffrey Del Carmen Sold A Bunch Of Shares In Catalyst Pharmaceuticals - Simply Wall St
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock - Investing.com India
Carmen Del Sells 30,423 Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus.com
Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock - Investing.com
Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
When and Where to Hear Catalyst Pharmaceuticals' Future Plans: CEO Set for Major Healthcare Conference - StockTitan
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $32.00 at Robert W. Baird - Defense World
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges - Seeking Alpha
Catalyst Pharmaceuticals’ (CPRX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to Strong-Buy at StockNews.com - Defense World
Sanctuary Advisors LLC Has $1.24 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates - MSN
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap UpHere's What Happened - MarketBeat
Catalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reaffirmed at Stephens - MarketBeat
Oppenheimer Adjusts Price Target on Catalyst Pharmaceuticals to $32 From $31, Maintains Outperform Rating - Marketscreener.com
Ieq Capital LLC Invests $313,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Principal Financial Group Inc. Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Reports Record 2024 Financial Results - TipRanks
Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges - TipRanks
Catalyst Pharmaceuticals (NASDAQ:CPRX) Announces Quarterly Earnings Results - MarketBeat
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today - MSN
Catalyst Pharmaceuticals Inc (CPRX) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations - Investing.com
Catalyst Pharmaceuticals Inc (CPRX) 財務データ
収益
当期純利益
現金流量
EPS
Catalyst Pharmaceuticals Inc (CPRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Option Exercise |
2.24 |
44,904 |
100,585 |
113,777 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 06 '25 |
Sale |
21.67 |
180,096 |
3,902,680 |
68,873 |
| INGENITO GARY | Chief Med. & Reg. Officer |
Mar 05 '25 |
Sale |
22.09 |
44,904 |
991,929 |
68,873 |
1.66%
4.32%
大文字化:
|
ボリューム (24 時間):